Recurrent COVID-19 Diagnosis

The study duration: 24 Weeks.

Participants will attend 10 study site visits.

Compensation package includes:

$100 to patient for each site visit

All study medication, assessments and examinations are free to the participants.

Inclusion Questions:

Has the patient completion of a 5-day course of Paxlovid within the last 14 day?

Has the patient tested positive for COVID-19 in the last 24 hours? (YES/ NO)

Is the patient experiencing any symptoms of COVID-19?

Patient’s other medical conditions:

Inclusion Criteria

Participants are eligible to be included in the study only if all the following criteria apply:

Participants aged 12 years or older
Currently positive for COVID-19
Participants must have written documentation showing completion of a 5-day course of Paxlovid (nirmatrelvir/ritonavir).
They must have symptom alleviation or resolution in COVID-19 signs/symptoms followed by a worsening (rebound) of signs/symptoms after completing an initial 5-day course of Paxlovid (nirmatrelvir/ritonavir).
The onset of rebound in COVID-19 symptoms must occur within 2 weeks (14 days) after the completion of the initial 5-day course of nirmatrelvir/ritonavir.

You can have them call us at the number below and we will assess them for eligibility.